The Headache Inducing Effects of Cilostazol on Migraine Patients

Migraine Clinical Trial

Official title:

The Headache Inducing Effects of Cilostazol on Migraine Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01841827
• Other study ID #: H-2-2013-033
• Status: Completed
• Phase: N/A
• First received: April 20, 2013
• Last updated: June 5, 2014
• Start date: April 2013
• Est. completion date: June 2013

Study information

• Verified date: June 2014
• Source: Danish Headache Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Health and Medicines Authority
• Study type: Interventional

Clinical Trial Summary

We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosed with migraine without aura according to the IHS criteria from 2004.

• Healthy besides migraine

Exclusion Criteria:

• Tension-type headache more than 3 days per month

• Other types of primary headaches

• Pregnancy

• History of vascular diseases or psychiatric diseases.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• Cilostazol

• Placebo

Locations

Country	Name	City	State
Denmark	Danish Headache Center & Department of Neurology	Copenhagen	Glostrup

Sponsors (1)

Lead Sponsor	Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo.	Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months.	Outcome measure will be done within 3 month. Final data will be presented within 6 months	No